Cardiome shares battered after FDA places clinical hold on vernakalant Phase III trial
This article was originally published in Scrip
Shares of Cardiome Pharma sank 25% in premarket trading on 21 October after the company announced that an unexpected case of cardiogenic shock forced investigators at its partner, Astellas Pharma, to halt enrollment for a key Phase III confirmatory study of the atrial fibrillation drug vernakalant injection.
You may also be interested in...
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.